US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

Stockholm, January 27, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030. BioArctic’s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid

Invitation to presentation of BioArctic’s Full Year Report for the period January - December 2020 on February 4 at 9.30 a.m. CET

Stockholm, Sweden, January 26, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)will publish the company’s Full Year Report for the period January – December 2020 onThursday, February 4, 2021, at 08:00 a.m. CET. In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on February 4, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Full Year Report for the period January – December 2020, followed by a Q&A-session. To attend, please dial-in at one of

BioArctic winner of the Allbright Award 2020

Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ceremony in Stockholm. BioArctic is a Swedish research-based biopharmaceutical company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company is listed on Nasdaq Stockholm Mid Cap and has previously been nominated as a finalist for the

BioArctic presents Nomination Committee

BioArctic presents Nomination Committee Stockholm, Sweden, October 13, 2020 – BioArctic's Annual General Meeting on May 7, 2020, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the company shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2020, as well as the Chairman of the Board (convener). September 30, 2020, the three largest shareholders were Demban

Invitation to presentation of BioArctic’s Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET

Stockholm, Sweden, October 6, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on October 14, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Interim Report for the period January – September 2020 followed by a Q&A-session. To attend, please dial-in at one of the numbers below, from: Sweden:

Invitation to presentation of BioArctic’s Interim Report for the period January - June 2020 on July 10 at 9.30 a.m. CET

Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)to publish the company’s Interim Report for the period January – June 2020 onFriday, July 1, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analystsand media on July 10, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – June 2020 followed by a Q&A-session. To attend, please dial-in at one of the numbers below, from: Sweden: + 46 8 505 583 55

Members of BioArctic’s Board of Directors and management increase their shareholdings

Stockholm, Sweden, May 26, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have exercised options to purchase shares in the company in accordance with the existing option agreements with the principal owners of BioArctic AB. Seven members of BioArctic's Board of Directors and management, including the CEO of the company, Gunilla Osswald, have today exercised their options to purchase shares in the company in accordance with the option agreement previously concluded with the principal owners of BioArctic AB.

Report from Annual General Meeting in BioArctic (publ)

Stockholm, Sweden, May 7, 2020 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting.  The following resolutions were adopted. Adoption of the income statement and the balance sheet; allocation of result The general meeting adopted the income statement and balance sheet for the company and for the group in accordance with submitted accounting documents. The general meeting further resolved to allocate the company’s result in accordance with the board’s proposal, i.e. that profits of SEK 833,968,288 shall be carried forward. The resolution entails that

Invitation to presentation of BioArctic’s Interim Report for the first quarter 2020 on April 22 at 9.30 a.m. CET

Stockholm, Sweden, April 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)to publish the company’s Interim Report for the period January – March 2020 onWednesday, April 22, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analystsand media on April 22, at 09:30 CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment onthe Interim Report for the period January – March 2020 followed by a Q&A-session. To attend, please dial-in at one of the numbers below, from: Sweden: + 46 8 505

Notice of Annual General Meeting in BioArctic AB (Publ)

The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 7 May 2020 More information about the contents of the proposals may be obtained from the complete notice to the Annual General Meeting below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar), in Svenska Dagbladet and on the company's website within the next few days.For more information, please contact:Jan Mattsson, CFO, +46 70 352 27 72, jan.mattsson@bioarctic.se   NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC

BioArctic publishes the Annual Report for 2019

Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in Swedish. The Annual Report, which is attached in Swedish, can also be downloaded from the company’s Swedish website, www.bioarctic.se (Investerare/Finansiella rapporter). An English translation of the Annual report is estimated to be available on the webpage on April 17, 2020. For further information, please contact: Jan Mattsson, CFO, telephone + 46 (0) 70 352 27 72 This information is information that BioArctic AB (publ) is obliged

Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401

Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401. The enrollment of patients with early Alzheimer’s disease will be carried out at memory clinics at four Swedish university hospitals. The global study was initiated in spring 2019 and, according to Eisai, results from the study are expected in 2022. BAN2401 is an antibody that helps the body to eliminate accumulations of misfolded amyloid beta protein. BAN2401 attacks

BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019

Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by BioArctic and its partner, Eisai, at the Alzheimer’s Association International Conference® 2019 (AAIC®) in Los Angeles, USA. BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid beta. The new data included details of the binding profile of BAN2401 and additional analyses from the earlier presented Phase 2b study in 856 patients with early

BioArctic’s co-founder received AAIC Lifetime Achievement Award

Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer’s diseaseStockholm, Sweden, July 15, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University and researcher, received one of the world’s most prestigious awards in Alzheimer’s disease research. The award is called the “Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research” and was given out during the ongoing Alzheimer’s Association International Conference® (AAIC®) 2019

BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment

Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. Per-Ola Freskgård to strengthen BioArctic’s development of its technology platform to facilitate passage of antibodies and other biologics across the blood-brain barrier. The objective with BioArctic’s novel technology is to be able in the future to apply it to the company’s own antibodies, and also for other companies to apply it in development of their antibodies. Through the recruitment of Dr. Freskgård, BioArctic

BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease

Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease. Eisai is responsible for the clinical development of BAN2401, including this confirmatory Phase 3 study, and BioArctic is entitled to milestone payments and royalties. The total value of the payments to BioArctic under the collaborations can amount to

BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease

Stockholm, Sweden, March 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease. The confirmatory Phase 3 study in early Alzheimer´s disease patients will according to Eisai be initiated in March 2019 and the final readout of primary endpoint is targeted for 2022. The previously announced open-label extension study for patients priorly enrolled in the Phase

BioArctic presents Nomination Committee and publishes financial calendar 2019

Stockholm, Sweden, November 6, 2018 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2018 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee. If any of the three largest shareholders does not wish to appoint a member of the

BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease

Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie (NYSE: ABBV) and BioArctic. The option is subject to filing and clearance under the US Antitrust legislation. BioArctic and AbbVie, a global biopharmaceutical company, in 2016 entered into a strategically important collaboration to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018

Stockholm, Sweden, October 30, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on November 8, at 09:30 – 10:30 a.m. CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – September 2018 followed by a Q&A-session. To attend, please dial-in at one of the numbers below from:

BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference

Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical Phase 2b study with BAN2401 in 856 patients with early Alzheimer’s disease (AD). BAN2401 is a selective anti-amyloid beta (Aβ) protofibril antibody. Statistically significant benefits were observed on the key efficacy endpoints at 18 months on slowing progression in Alzheimer’s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured by using amyloid-PET (Positron Emission Tomography)

BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease

Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant the company’s patent application in Europe, EP09738534.8, for its Parkinson’s disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018. The granted concept patent in Europe protects the company’s innovative treatment strategy for Parkinson’s disease. Corresponding patents have previously been granted in the US and Japan. BioArctic’s patent

BioArctic signs a research agreement with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease

Stockholm, Sweden, September 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). BBS was founded by the internationally well-known researchers in the area of Alzheimer diagnostics, Professors Kaj Blennow and Henrik Zetterberg and University of Gothenburg in Sweden. The objective of the research collaboration is to develop new and improved diagnostic methods for Alzheimer’s disease by identifying and measuring new biomarkers in cerebrospinal fluid (CSF) and blood. The goal is to be able to better

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media